Kenvue – Newsology

Health

Here’s what Jim Cramer thinks about J&J stock after a pivotal talc case verdict

Newsology1 year ago011 mins

[ad_1] A closely watched talc trial in California goes against Johnson & Johnson (JNJ), adding uncertainty around whether tens of thousands of other plaintiffs suing the company will sign on to J & J’s proposed $8.9 billion settlement offer or seek to get their own days in court. Jim Cramer believes the biopharmaceutical company was…

Health

Ford’s dividend quality, J&J’s split-off, cost basis discipline — what we think about all these

Newsology1 year ago016 mins

[ad_1] Send your questions directly to Jim Cramer and his team of analysts at investingclubmailbag@cnbc.com . Reminder, we can’t offer personal investing advice. We will only consider more general questions about the investment process or stocks in the portfolio or related industries. Question 1: What are your thoughts on the stability of FORD’s dividend? Thank you, Denise The…